|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsor: | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |
|---|---|
| Information provided by: | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |
| ClinicalTrials.gov Identifier: | NCT00038974 |
Purpose
This study is designed to test the hypothesis that African-Americans respond less well to combination pegylated interferon and ribavirin therapy than Caucasian-Americans who have chronic hepatitis C genotype 1 and who were not previously treated with either interferon or ribavirin. Reasons for differences in response, regardless of race, will be studied.
| Condition | Intervention | Phase |
|---|---|---|
|
Hepatitis C |
Drug: Pegylated interferon Drug: Ribavirin |
Phase III |
| Study Type: | Interventional |
| Study Design: | Allocation: Non-Randomized Endpoint Classification: Efficacy Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Study of Viral Resistance to Antiviral Therapy of Chronic Hepatitis C (Virahep-C) |
Eligibility| Ages Eligible for Study: | 18 Years to 70 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion:
Exclusion:
Contacts and Locations| United States, California | |
| University of California, San Francisco | |
| San Francisco, California, United States, 94143 | |
| United States, Florida | |
| University of Miami School of Medicine | |
| Miami, Florida, United States, 33136 | |
| United States, Illinois | |
| Rush University | |
| Chicago, Illinois, United States, 60612 | |
| United States, Maryland | |
| University of Maryland School of Medicine | |
| Baltimore, Maryland, United States, 21201 | |
| United States, Massachusetts | |
| Beth Israel Deaconess Medical Center | |
| Boston, Massachusetts, United States, 02215 | |
| United States, Michigan | |
| University of Michigan Medical Center | |
| Ann Arbor, Michigan, United States, 48109 | |
| United States, New York | |
| New York-Presbyterian Medical Center | |
| New York, New York, United States, 10032 | |
| United States, North Carolina | |
| University of North Carolina | |
| Chapel Hill, North Carolina, United States, 27599 | |
More Information
| ClinicalTrials.gov Identifier: | NCT00038974 History of Changes |
| Other Study ID Numbers: | Virahep-C (completed), U01 DK60329 |
| Study First Received: | June 5, 2002 |
| Last Updated: | March 15, 2011 |
| Health Authority: | United States: Food and Drug Administration |
|
Hepatitis C Interferon Ribavirin Efficacy |
Viral load Genetics Cytokines Immunology |
|
Hepatitis Hepatitis A Hepatitis C Liver Diseases Digestive System Diseases Hepatitis, Viral, Human Virus Diseases Enterovirus Infections Picornaviridae Infections RNA Virus Infections |
Flaviviridae Infections Antiviral Agents Interferons Ribavirin Anti-Infective Agents Therapeutic Uses Pharmacologic Actions Antineoplastic Agents Antimetabolites Molecular Mechanisms of Pharmacological Action |